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ACA Anterior Cerebral Artery 
AcomA Anterior Communicating Artery 
AGF Angiography 
aSAH  aneurysmal subarachnoid haemorrage 
BA Basilar Artery 
CI Confidence Interval 
COPD chronic obstructive broncopulmonary disease 
CS Caesarean Section 
CSF Cerebrospinal Fluid 
CT Computed Tomography 
CTA Computed Tomographic Angiography  
DSA Digital Subtraction Angiography 
GCS Glasgow Coma Scale 
GOS Glasgow outcome Score 
ICA Internal Carotid Artery 
MCA Middle Cerebral Artery 
MRA Magnetic Resonance Angiography 
MRI Magnetic Resonance Imaging 
NA Not Available 
NCCU Neurosciences Critical Care Unit 
NIS Nationwide Inpatient Sample  
PCA Posterior Cerebral Artery 
PcomA Posterior Communicating Artery 
PICA Posterior Inferior Cerebellar Artery 
SD Standard Deviation 
SIADH Syndrome of inappropriate antidiuretic hormone section 





Background: Aneurysmal subarachnoid haemorrhage (aSAH) during pregnancy represents an 
important cause of maternal and foetal morbidity and mortality. Approaches to diagnostics and 
treatment are still controversial and there are only a limited number of cases described in the literature. 
Our study examines the management of aSAH in pregnant patients creating a case series by combining 
patients from our hospital records with those from the limited available literature. 
Methods: Cases published between January 1995 and January 2015 were studied. Chi-squared test, 
exact Fisher's test, and chi-squared test for trend were used for analyzing categorical data, whilst t-test 
and U Wilcoxon-Mann-Whitney test for continuous data. 
Results: 52 patients were included. The mean age was 31.47±5.80 and most patients were in their third 
trimester. A univariate pooled data analysis suggested that the maternal outcome may depend on 
mother’s age, mother’s Hunt and Hess score and Glasgow Coma Scale at arrival, treatment modality 
for the aneurysm, mode and timing of delivery. However, at the multivariate analysis only the presence 
of general complications resulted to significantly impact on maternal outcome. 
Conclusions: Ruptured aneurysms in pregnant patients with aSAH may be safely secured in a timely 
manner. The diagnostic and treatment strategy for each of these patients should consider peculiar 
maternal and obstetric factors and requires a multidisciplinary assessment involving obstetrics, 
neurosurgeons and intensivists. Considering the observed statistical power of our series, our findings 
should be taken with caution and should be supported by further systematic data collection. 
Keywords: pregnancy; subarachnoid haemorrhage; delivery; cerebral aneurysm. 
	 4	
Introduction 
Aneurysmal subarachnoid haemorrhage (aSAH) during pregnancy is an uncommon event, affecting 
only between 0.01 and 0.058% of pregnant women [11, 39]. As a result, published literature on the 
management and outcome is limited. However, it is the third leading cause of maternal death from 
non-obstetric causes, accounting for 5% to 12% of total mortality during pregnancy and it is associated 
with serious morbidity of both mother and foetus [11]. Several para-physiological changes occur in the 
human body during pregnancy, such as hormonal and hemodynamic changes including alterations to 
blood pressure and increased plasma volumes [53]. Hormones (oestrogen, progesterone, human 
chorionic gonadotropin) can lead to a remodelling of the arterial and venous intima and media [48]. 
Such structural changes of the arterial wall are mechanisms implicated in aneurysm formation and 
rupture [2]. However, the pathophysiology of aSAH is more complex and poorly understood. The role 
of sex hormones is far from clear. Oestrogen has been shown to confer some protection from aSAH 
[18, 34, 52]. At the same time, evidence from epidemiological studies of the prevalence of SAH in 
women and men or in women taking hormone replacement therapy (HRT) is not clear cut [38], and it 
has not been conclusively demonstrated that aneurysm rupture is more frequent in pregnancy. 
 
The risk of rebleeding after aSAH is greatest in the first 2 to 12 hours and has an incidence in the range 
of 4-13.6% within the first 24 hours, rising up to 10–20% in the first month [4, 43]. As a consequence, 
it is generally accepted that ruptured aneurysms should be secured as early as possible [45, 53]. The 
mortality from aSAH in pregnant untreated patients is twice as high as in treated patients (10.2% 
versus 5.2%[26]). Thus, treatment principles for pregnant patients with ruptured intracranial aneurysms 
should not differ from those applied to non-pregnant patients.  
Diagnostic and management strategies are complicated by maternal-foetal considerations: there is an 
understandable clinical anxiety in pursuing invasive interventions in pregnant patients. Furthermore, 
inclusion of these patients into randomized research studies is of ethical concern and there is a paucity 
of high-quality literature regarding the optimal management and outcomes of gravid patients with 
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concomitant neurological critical illness.  
In this manuscript we pool published case reports and series in the literature with data from our 
retrospective analysis of obstetric patients admitted for aSAH to our tertiary specialist neurosciences 
critical care unit. Our aim is to create a series of sufficient number to characterize the presentation of 
aSAH in pregnancy, and to synthesize an overview of contemporary management strategies and 
outcomes of this rare but nevertheless important disease.  
Methods 
Data collection 
Using routinely collected registry data, we obtained a list of gravid and peripartum patients (within 
three weeks of delivery) admitted to our Neurocritical Care Unit between 1st January 2000 and 1st 
January 2015. Our series was complemented by an extensive literature review performed by searching 
PubMed/MEDLINE including references between January 1995 and January 2015 using the search 
terms ‘pregnancy’, ‘subarachnoid haemorrhage’, and ‘ruptured intracranial aneurysm’ with wild-card 
options and Medical Subject Headings (MeSH) terms where appropriate. Only English language 
articles were included. All published case reports and case series on pregnancy related aSAH were 
considered relevant and selected for review. Additional material was obtained from the reference list of 
selected articles. Review articles were not retained in our analysis but bibliographies were scanned to 
increase the yield of potentially relevant manuscripts. 
Statistical analysis 
Data were checked for deviation from normal distribution (D’Agostino and Pearson omnibus normality 
test) and homogeneity of variance. Chi-square, exact Fisher, and chi-square test for trend were used for 
analyzing categorical data, whilst t-test, t-test with Welch’s correction (in case of unequal variance) 
and Wilcoxon-Mann-Whitney U tests (in case of violation of normal distribution) for continuous data. 
Prognostic variables are tabulated both as raw and as adjusted, after adjusting for confounding 
variables (demographic variables). When performing multivariate analysis, also F-statistics, overall 
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fitting R2 (raw and adjusted), partial 2 and observed statistical power were computed. Analysis was 
carried out with MedCalc® (Version 15.8, MedCalc software bvba) and SPSS version 22.0 (IBM Corp. 
Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp). For all the 
analyses a 5% significance level was set. 
 
Results 
A total of 22 papers reporting aSAH in pregnancy were found, constituting data from a total of 45 
patients. Reports ranged from single cases (13 papers) to a maximum of seven cases (one case included 
in [50] had an unruptured aneurysm) (Table 2). Study details are shown in tables 1 and 2, whilst the 
results of our pooled analysis are tabulated in table 3 and 4. In one study that describes 8 patients with 
spontaneous SAH in pregnancy, only 1 case was presented with adequate details to be included in this 
case series [47].  
 
Cumulative results: 
Within this cumulative series 52 cases of pregnant patients affected by aSAH, mean age was 31.5±5.8 
(range 20-42; median 31). 73.1% of patients (n=38) were in their third trimester, 19.2% (n=10) in their 
second and 7.7% (n=4) in the first trimester. More specifically, the mean gestation was 29.0±8.10 (9-
39; 32); three cases were not specified, one case occurred was during labour [20], another case was one 
hour after CS and the third case on day 12 postpartum [5]. The presence (61.9%, n=13) or absence 
(38.10%, n=8) of risk factors was reported in 21 cases. Hypertension was the most common risk factor 
(affecting six patients, 30% of our cumulative series), followed by older age (3 patients were older than 
40 years), and finally by alcohol and cigarette abuse (two cases). Chronic obstructive pulmonary 
disease, gestational diabetes, and familiarity for ruptured aneurysm were present in just one patient.  
Two patients had a history of previously complicated pregnancy by preeclampsia and one by 
eclampsia. 
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Headache was the most frequent presenting symptom in our cumulative series, affecting 79.6% of the 
patients (nearly all the non-comatose patients). Signs which might be associated with intracranial 
hypertension (confusion, vomiting, neurological deterioration) were seen in half of SAH patients 
(53%); 14.3% presented with focal signs, and seizures were present in 14.2% cases. Seizures were the 
only sign at presentation of two patients. Two cases presented with cardiogenic shock, and for three 
cases symptoms at presentation were not reported. 
Mean GCS at presentation (not available in one case) was 12.8±3.9 (3-15; 15). Mean Hunt and Hess 
score (8 cases not available) was 2.7±0.9 (2-5; 2). Fisher score was described for 67.3% (n=35) 
patients. Of these cases, 65.7% (n=23) presented a Fisher Score IV, and 34.3% (n=12) with Fisher 
score between I and III. Moreover, CSF diversion was reported in 5 patients (see Table 2). 
Including the Posterior Communicating Artery (PcomA) aneurysms (7 cases) within the anterior 
circulation aneurysms, the distribution of the aneurysms was in the 76.9% of the patients in the anterior 
circulation (n=15 Internal Carotid Artery or ICA, n=9 Middle Cerebral Artery or MCA, n=6 Anterior 
Communicating Artery or AcomA, n=2 Anterior Cerebral Artery or ACA, n=7 PcomA) and 23.0% in 
the posterior circulation (n=8 Vertebral Artery or VA, Basilar Artery or BA, Posterior Inferior 
Cerebellar Artery or PICA and n=4 Posterior Cerebral Artery or PCA). In one case the patient had 
multiple aneurysms and the site of the ruptured is not specified; it was likely to have involved the 
anterior circulation [5]. In terms of diagnostic procedure (5 cases are not specified), CT followed by 
CT-angiography (CTA) or digital subtraction angiography (DSA) was used in 9 and 31 cases 
respectively. Only in three cases did diagnosis and treatment avoid ionizing radiation entirely (MRI 
followed by MR angiography (MRA) and aneurysm clipping). In one case [46] CS was performed 
after diagnostic MRA and DSA was acquired thereafter. 
Aneurysm occlusion was achieved by surgical clipping in 53.8% of the cases (n=28), and with an 
endovascular procedure in 36.5% (n=19). 9.6% (n=5) did not receive any treatment; in one of these, 
the aneurysm thrombosed spontaneously and in three cases no treatment was possible due to the 
critical condition of the mothers. Timing of delivery with respect to treatment to secure the aneurysm 
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was available in 49 of 52 cases: At term in 14.3% (n=7) and after treatment in 30.6% (n=15), before 
treatment in 24.5% (n=12), and at the same time as treatment in 22.4% (n=11). One foetus was aborted 
after endovascular treatment at the eleventh week of pregnancy, and 2 foetuses died in utero as a 
consequence of the death of their mothers. One patient (2.0%) did not require any treatment.  
Data on the mode of delivery was available for 49 out of 52 women; three women (6.4%) did not 
deliver at all (one abortion and two deaths in utero). Of the remaining 46 patients, 72.3% (n=34) had a 
CS, of which more than 70% were emergency procedures. The remaining 25.5% (n=12) had a vaginal 
delivery. Vasospasm / delayed cerebral ischaemia was reported in 9 cases, being present in 8 patients 
(88.9%) and absent in 1 patient (11.1%). Other general / non-specific complications were reported in 
16 cases (32.6%): SIADH (one case), infective complications (3 cases), cardiopulmonary 
complications (3 cases), cerebral oedema (3 cases), and rebleeding (2 cases). 33 patients (67.3%) did 
not report any general complications. 
Mean maternal GOS was 4.2±1.37 (1-5; median 5). A good outcome of the mother (GOS=4 or 5) at 
discharge was observed in 84.6% (n=44 cases). Six women died during hospitalization and one died 
seven days after discharge making a total of 14% mortality. Two patients had a GOS of 3. Hunt-Hess 
score at admission (1-3 versus 4-5) strongly correlated with GOS (4-5 versus 1-3) (X2 test; p=0,0019), 
whereas the Fisher Score (1-3 versus 4) did not (X2 test; p=0,38). No association between the mode of 
delivery and the mother’s GOS (X2 test; p=1) was found. 
Outcome of the babies was available for 44 out of the 54 cases (two twins). 84.1% (n=37) of the babies 
had a good condition at birth (defined with Apgar score ≥4). Seven  (15.9%) had a low Apgar score 
(between 1 and 3); two babies died in utero; two immediately after birth, one pregnancy was 
terminated, making a total of 5 deaths (11.4%). The outcome of the baby seemed to depend on mode (p 
<0.001) and timing (p <0.001) of delivery, Hunt and Hess score (p=0.014) and GCS at arrival 
(p=0.047) (see Table 2). Statistical findings from pooled data analysis with respect to maternal and 
baby outcome are shown in table 3. Treatment modality, timing and mode of delivery, Hunt and Hess 
Grade, GCS, general complications, trimester of presentation and maternal age were found to be 
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significantly correlated with maternal outcome. Treatment modality, timing and mode of delivery, 
Hunt-Hess Grade and GCS were found to be statistically correlated with fetal outcome. 
In contrast to the above univariate results, in a multivariable model (Table 4) only general 
complications were found to have a statistically significant impact on maternal outcome. In particular, 
the presence of general / non-specific complications is characterized by an odds-ratio (OR) of 1.45 
[95% CI 1.16-1.82] of having a poor outcome. No variable resulted to have an influence on baby 
outcome.  
Discussion 
This case series of clinical data from gravid and peri-partum patients with aSAH – extracted from a 
retrospective analysis of internal cases and from published literature – aims to present the largest 
available picture of this unique group of patients.  
The mean age of this cumulative series described is similar to that reported by a Nationwide Inpatient 
Sample (NIS) (30.3±8.0) [26], and it is much lower than the average age of female aSAH in general 
[6]. According to this database (NIS), the prevalence of unruptured aneurysms among all women of 
pregnancy age is 1.8%. Kim et al. [26] suggested that the risk of aneurysm rupture during pregnancy is 
not increased as compared to the general population of the same age and sex (1.4%; 95% CI = [1.35-
1.57]). However, an increase in risk of rupture seems towards the third trimester with a peak during 
labour and delivery [57], and our results support this. Indeed, 73% of the patients of our cumulative 
series presented in the third trimester of pregnancy or peripartum (defined as within 3 weeks from 
delivery).  
Risk factors and presentation in pregnant aSAH patients are similar to those commonly reported for 
aSAH patients in general. However, a history of hypertension is present in two thirds of aSAH patients 
in general [33] and yet it features in just 10-20% of aSAH cases in pregnancy [36]. Tobacco smoking 
[23] is described in half of aSAH patients [33]. Less common risk factors are hypercholesterolemia, 
alcohol abuse and diabetes mellitus [33], which are also present in pregnant patients. In addition, 
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eclampsia is involved in 14–40% cases of intracranial haemorrhages and risk increases in the 
postpartum period [28].  
Headache is the most common symptom at presentation [12] and can be associated with nausea and 
vomiting as well [15] or with signs of meningism such as neck stiffness, affecting up to 90% of the 
patients (reviewed in  [53]). In the general aSAH population, seizures occur at presentation in 3 - 21% 
of cases [10], similarly to our cumulative series of pregnant aSAH patients. Focal neurological signs 
were less common in our series than the literature reports for pregnant aSAH patients (14,3% vs. 30%) 
[53].  
Radiation protection is of particular concern for both the diagnosis and the choice of treatment strategy 
because of the risks of radiation exposure to the foetus. The traditional preoperative assessment for 
aSAH patients in general, typically includes CT followed by CTA, DSA or less frequently by MRA 
[27]. Whereas a head CT scan involves an exposure of 1.1-2.5mSv, a CTA typically involves 3.57-
5.73 mSv and 2-dimensional DSA has an even higher radiation burden of around 10.5 mSv [1]. 
However, these are whole body doses and do not necessarily reflect the dose to the foetus. Indeed, 
some studies have concluded that the risks for the foetus associated with CT are very low [55]. Some 
authors have argued that magnetic resonance imaging (MRI) is to be preferred [29]. However, MRI is 
less ubiquitously available and scanning times are much longer than with CT and so agitated patients 
may require sedation. Therefore, for most of the cases that we present, a CT followed by CTA or DSA 
was performed for the diagnosis. In one case ([46], case 1), MRA confirmed a ICA aneurysm, and 
endovascular coiling with DSA was performed after emergency CS to avoid the risk of foetal exposure 
to radiations. Even for treatment, the endovascular procedure is associated with a radiation dose to the 
foetus of 4.9 mSv, considered below the teratogenic dose [35].   
The choice of the aneurysm treatment method is very controversial. According to the International 
Subarachnoid Aneurysm Trial (ISAT) [40], most of the aneurysms (97.3%) are located in the anterior 
circulation; our revised series similarly showed a clear-cut prevalence of aneurysms for that region 
(75%). In our review anterior or posterior circulation aneurysm location did not seem to associate with 
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a specific choice of treatment modality (clipping or coiling). This confirms that indications for either 
clipping or coiling are not clear-cut since in most cases both are regarded as technically feasible [7]. 
Aneurysm location did not seem to relate to clinical (Hunt Hess score; Welch’s t-test p-value=0.059, 
statistically borderline) or radiological grade (Fisher grade) at admission. However, in the present 
series, all treated BA aneurysms were coiled in line with the current trend in practice [7]. In general, 
local experience is probably most important in determining treatment modality [7].  
We did not see any relationship between clinical (Hunt-Hess score) or radiological grade (Fisher 
grade) at admission and choice of treatment modality employed. Reports are controversial [32] 
regarding the choice of treatment modality in relation to clinical grade, but other authors also observed 
that clinical outcomes seem not to differ between clipped or coiled patients [30, 51].  
The utility of surgery for Fisher grade IV patients in prevention of complications of vasospasm and 
need of permanent ventricular shunt is not appraised by all authors [21, 56], though several studies are 
in favour of its efficacy [60, 61]. In this cumulative series, coiling or clipping are not even influenced 
by the trimester of pregnancy at presentation. However, clipping should be performed when delivery is 
not possible before treatment to avoid the foetal risks associated with endovascular treatment 
(prolonged radiation exposure, the need for systemic anticoagulation, the risk for incomplete aneurysm 
exclusion or post procedural rupture) [30]. Moreover, the angiography suite can be a hazardous 
environment in the event of foetal distress, with limited monitoring or equipment to facilitate a 
potential precipitous delivery [35]. Kim et al. [26] do not provide any information about timing of 
delivery in respect to treatment of the aneurysm. Nevertheless, the increasing trend [29, 37, 46] 
towards the use of coiling in pregnancy, as in our review, is likely to be motivated by both ISAT 
studies [40, 41].  
Another important consideration is the mode and timing of delivery. This decision requires a 
multidisciplinary discussion that should involve neurosurgeons, intensivists, obstetricians, 
neonatologists and anaesthetists, and should take into consideration the condition of both the mother 
and of the foetus. Although there are no expert guidelines concerning the obstetric management of 
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pregnant patients affected by aSAH, emergency CS should be considered when the clinical state of the 
mother is life-threatening (coma, brainstem damage), if the interval between the treatment of the 
aneurysm and labour is likely to be less than 8 days, and if the diagnosis of the aneurysm is in a late 
stage of pregnancy [42]. In particular, for gestational ages beyond 34 weeks (reviewed in [53]) an 
emergency CS should be considered. By contrast, in the early stages of pregnancy (and in particular 
before the 24th gestational week) the expected survival rate for the foetus is very low and the patient 
should be treated essentially as if not pregnant [22, 31, 46]. 
Between the 24th and 34th week, each case should be considered and evaluated according to the 
conditions of the mother and of the foetus following a multidisciplinary discussion. We found that 
decisions regarding the timing of delivery with respect to aneurysm treatment was not influenced by 
the clinical conditions of the mother at presentation or by neuroradiological findings (Fisher score), 
instead only depending on the trimester of aSAH presentation. Thus, women who present with aSAH 
in the first and second trimester are usually treated like non-pregnant patients, undergoing treatment of 
the aneurysm before continuing their pregnancy at term. Patients who present symptoms in their third 
trimester show an increased rate of delivery previous to aneurysm treatment. 
Once the aneurysm is secured, pregnancy can be allowed to progress to term. Since delivery mode 
could have an impact on maternal outcome, the decision for the delivery option should be based on 
clinical (neurological, obstetric) indications. Indeed in our cohort, the mode of delivery had no 
significant correlation with the trimester of aSAH presentation and did not influence outcome. 
Although in principle there is no neurosurgical contraindication to vaginal delivery following 
aneurysm occlusion [11], CS might be preferable under some circumstances such as if labour is likely 
to occur shortly after treatment of the aneurysm, or if there is an incomplete occlusion of the aneurysm 
[40].  
The choice for timing of delivery also strongly depends on the choice of treatment modality for the 
aneurysm. Clipping is usually performed before or at the same time as CS. Once the baby has been 
delivered, both endovascular or surgical treatment are options as with any other aSAH patient. 
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Moreover, according to our analysis (table 3), mothers who delivered after or at the same time as 
aneurysm treatment had a better outcome. 
Vasospasm/delayed cerebral ischemia was reported for only 15% cases in our series. This percentage 
represents a lower incidence compared to general literature that suggests symptomatic vasospasm 
occurs in about 30% of aSAH patients [62]. This complication may be likely underestimated/under-
reported by several authors, or perhaps there could be some protective factors in pregnancy (such as 
haemodilution and hypervolemia) [6]. Of those patients that survived vasospasm, all had a good 
outcome at discharge. Fatal complications were cardiopulmonary arrest [25] and cerebral oedema [50], 
however all these four cases had GCS 3 at presentation and thus were already in severe conditions at 
arrival.  
Our results show that most of the patients fully recovered and had no significant neurological deficits 
at discharge, with GOS score in the range 4-5 (83%). As expected, GOS was strongly linked to clinical 
condition at presentation (Hunt-Hess score) [19, 24]. Three of our revised cases presenting with 
cardiogenic shock and/or coma and thus with a very severe Hunt-Hess score and low GCS [5, 25, 50] 
died. This, again, confirms data from the literature claiming that conditions at arrival are prognostic for 
short-term outcomes [16, 19, 24]. 
Aneurysmal SAH in general is characterized by a high mortality rate in the acute phase between 8 and 
67% [44]. In our review one mother in every ten with aSAH died, and this confirms that mortality from 
aSAH in pregnancy is still remarkable (9.5% [26]), ranging from 13 to 85% (reviewed in [53]).  
Even though most of the babies had a good outcome, foetal mortality is still appreciable. All the 4 
cases of death in utero were the consequence of maternal death, and independent from mode of 
delivery. In one case the foetus was aborted after endovascular treatment of the aneurysm, though 
information on the indications were not available.  
In summary, our univariate pooled data analysis (table 3) showed that the maternal outcome may be 
related to the mother’s age, mother’s Hunt-Hess score and GCS at arrival, treatment method for 
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securing the aneurysm, mode and timing of delivery. The foetal outcome may be determined by 
maternal neurological status at arrival (Hunt-Hess score and GCS), as well as mode and timing of 
delivery. However, at the multivariate analysis (table 4), only the presence of general / non-specific 
complications was found to independently predict on maternal outcome (with an odds-ratio of 1.45 
[95% CI 1.16-1.82] of a poor outcome); no other variables (treatment modality, timing and modality of 
delivery, trimester of presentation, clinical presentation and maternal) had a statistically significant 
influence on foetal outcome. 
Unfortunately, there is little published data available as only single cases or very small series have 
been reported. Aside from overviews obtained from database registries [26], we found just 45 cases 
with detailed descriptions over the past 20 years during which coiling has been an established practice. 
The present cumulative series represents a synthesis of these cases and is the first with a statistical 
analysis and the first to describe aspects that are not available in other studies. However, because of the 
small case series, the statistical power of our findings in generally low (table 4), and thus our final 
findings and conclusions should be taken with caution.  
Despite these limitations, we suggest a flowchart that summarizes the typical clinical management 
strategy for aSAH during pregnancy according to current published practice and our discussion (figure 
1).  
Conclusions 
In conclusion, aSAH management and treatment strategy during pregnancy is still controversial. Early 
diagnosis and timely neurosurgical intervention can reduce the high maternal mortality and morbidity 
associated with aSAH. The choice of surgical treatment for securing the aneurysm and timing / mode 
of delivery should be evaluated on a case by case basis according to state of pregnancy, physiological 
condition and risk factors for the patient and for the foetus after a multidisciplinary assessment.  
Further research in the field is warranted. Whilst a devastating disease, aSAH remains rare in 
pregnancy and this motivates the establishment of a multinational registry as one possible way in 
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which to obtain sufficient data to develop more robust guidance and better risk models that could 
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Figure 1. Flowchart describing the management strategies of aSAH patients during pregnancy. As for non 
pregnant patients, the priority is to secure of the aneurysm. During the first and second trimester, when the foetus 
is still premature, patients should be treated as non pregnants; thus, after the treatment of the aneurysm (clipping 
(clp) or endovascular (ev) according to the location and the characteristics of the aneurysm), the pregnancy 
should be continued without any further precautions, and the modality of delivery should be the physiological 
vaginal modality, at term. In the third trimester when the foetus is at term, a CS is raccomanded before or 
contemporary to treatment in order to avoid any further risks (radiations, anticoagulation etc..) for the baby. 
 




















Kim et al., 2014 (24) 1 34 NA 16 2 NA drowsiness, SZ 14 5 4 
Surico et al., 2014 (52) 1 NA hemangioblast
oma, detected 
at SAH 
27 3 NA hypotension, SZ, neurological 
deterioration 
NA NA 3 
Tarnaris et al., 2014 (53) 1 21 NA 29 3 NA HA, third NP 15 3 NA 
Kataoka et al., 2013(23) 1 20 NA 26 2 NA left hemiparesis 12 NA NA 
2 34 NA 30 3 NA NA 14 NA NA 
3 36 NA 24 2 NA NA 15 NA NA 
4 34 NA 31 3 NA NA 15 NA NA 
5 42 NA 28 3 NA cardiopulmonary arrest 3 NA NA 
Bateman et al., 2012 (4) 1 41 NA NA 3 age,african american 
race, eclampsia 
SZ coma 3 5 4 




3 smoker, familiarity for 
ruptured aneurysm HT, 
preeclampsia 
HA 15 2 NA 
3 42 negative Post-
partum 
3 age HA photophobia 15 2 <4 
Guida et al., 2012 (16) 1 37 NA 34 3 NA HA, V, nucal rigidity 15 2 4 
2 34 NA 37 3 NA confusion, right hemiparesis 14 3 4 
3 41 NA 32 3 age letargia, focal deficit (not 
specified) 
12 3 3 
4 28 NA 33 3 NA SZ 14 2 2 
Ferreira et al., 2012 (13) 1 40 NA 32 3 NA HA, gait imbalance 15 2 4 
Elwatidy et al., 2011(12) 1 26 NA 36 3 NA HA, meningism 15 2 NA 
2 24 NA 22 2 NA HA, meningism LOC 15 2 <4 
Pumar et al., 2010(43) 1 30 negative 22 2 NA HA, V 15 NA 4 
Darbhamulla &  Reddy, 
2007 (8) 
1 22 HA 37 3 alchool abuse, HA drowsiness, HA, neck stiffnes 15 NA  
Riviello et al., 2004 (44) 1 37 neg 36 3 no HA, V, photophia 15 3 4 
Roman et al., 2004 (45) 1 28 NA 35 3 NA HA, confusion 14 3 4 
2 27 NA 34 3 NA nucal rigidity, anisocoria 15 2 4 
3 37 NA 12 1 NA dyplopia, retroorbital pain 15 2 NA 
4 30 HT 31 3 HT SZ 14 3 NA 
5 30 NA 32 3 NA HA, confusion, coma 3 5 4 
6 38 NA 38 3 NA HA, coma 3 5 4 
 7 33 HT 34 3 HT cardiogenic shock, coma 3 4 4 
Georgantopolou et al., 2003 
(14) 
1 32 NA 9 1 NA HA, vomit, neck stiffness 15 2 <4 
Kirzilikilic et al., 2003(27) 1 25 NA 10 1 NA HA, neck stiffness, third NP 15 3 diffuse 
2 39 NA 18 2 NA HA 15 2 4 
3 26 NA 28 3 NA HA 15 2 NA 
Hussain et al., 2001 (18) 1 29 NA during 
labour 
3 NA HA, third NP 15 3 NA 
Piotin et al., 2001(42) 1 28 NA 32 3 NA HA, V 15 3 NA 
2 31 NA 22 2 NA HA, V, LOC 15 3 NA 
Shahabi et al.,  2001 (48) 1 36 negative 38 3 no HA, LOC 15 2 NA 
Jaeger et al., 2000 (20) 1 38 NA 36 3 NA HA, LOC 3 5 4 
Meyers et al.,  2000 (34) 1 34 NA 11 1 no HA 15 2 3 
2 36 NA NA 3 NA HA 15 2 3 
3 36 NA NA 3 NA HA 15 2 diffuse 
Barker et al.,1998 (2) 1 29 NA 35  NA HA, V, photophobia, neck 
stiffness 
15 2 4 
D'Haese et al., 1997 (7) 1 29 NA 34 3 no HA,V, anisocoria 15 3 NA 
Kriplani et al., 1995(29) 1 25 negative 37 3 no HA, neck stiffness 15 2 <4 
2 24 negative 36 3 no HA, LOC  15 2 <4 
3 26 negative 36 3 no HA, LOC, neck stiffness 15 3 4 
PMH, past medical history; NA, not available; GCS, Glasgow Coma Score; SAH, Subarachnoid Haemorrhage;  HA, headache; HT, hypertension;; NA, not available; NP, nerve palsy; HA, 
headache; LOC, loss of consciousness; PMH, past medical history; SZ, seizures; V,  vomiting;  


































Kim et al., 2014 
(24) 
1 2 DSA PICA EV  after tr. cs no no  5 healthy 
Surico et al., 2014 
(52) 
1 3 MRA  & 
DSA 
ICA EV  after tr. NA no no  4 9,9 
Tarnariset al., 2014 
(53) 
1 3 MRA PcomA EV  after tr. cs no no  5 healthy 
Kataoka et al., 
2013(23) 
1 2 NA VA-
PICA 
CLP  at term cs no rerupture  5 healthy 
2 3 NA ACom
A 
CLP  contemp to 
tr. 
cs yes cardiomyopathy yes 5 healthy 
3 2 NA MCA CLP  contemp to 
tr. 
cs yes septic shock yes 5 healthy 
4 3 NA ACom
A 
CLP  contemp to 
tr. 
cs yes no  5 healthy 




 1 death 
Bateman et al., 
2012 (4) 
1 3 DSA PCom
A 





2 3 DSA Multipl
e 




 3 3 DSA ICA none  before tr. cs no no  5 NA 
Guida et al., 2012 
(16) 
1 3 DSA ACA CLP  before tr. v no no yes 5 NA 
2 3 DSA MCA EV  before tr. cs yes died 2 days later  1 NA 
3 3 DSA ACA EV  before tr. cs yes died 3 days later  1 NA 
4 3 DSA BA EV  before tr. v no no  3 NA 
Ferreira et al., 2012 
(13) 
1 3 DSA VA-
BA j 
CLP yes NA NA NA no yes 5 NA 
Elwatidy et al., 
2011(12) 
1 3 DSA ICA CLP  contemp to 
tr. 
cs yes no  5 healthy 
2 2 DSA MCA EV  after tr. v no no  5 healthy 
Pumar et al., 2010 1 2 MRA BA EV  after tr. cs NA NA  5 healthy 
(43) 
Darbhamulla &  
Reddy, 2007 (8) 
1 3 DSA ACom
A 
EV yes after tr. cs yes no  5 NA 
Riviello et al., 2004 
(44) 
1 3 DSA ACA EV  before tr. cs yes no  4 8,9 
Roman et al., 2004 
(45) 
1 3 DSA ICA EV  before tr. cs yes no yes 5 5,10 
2 3 DSA ICA CLP yes after tr. cs yes shunt  5 2,7  and 
3,9 
(twins) 
3 1 MRI        
(no CT) 
ICA CLP  after tr. v no no  5 10,10 
4 3 CTA ICA CLP  before tr. cs yes no  5 0,0 




 1 0,0 
6 3 CTA MCA none  death in 
utero 
none no brain herniation  1 death in 
utero 
7 3 DSA ICA CLP  before tr. cs yes brain herniation, 
rebleeding, 
 1 0,8 
Georgantopolou et 
al., 2003 (14) 
1 1 DSA PCom
A 
CLP  after tr. cs no osteomyelitis 
(bone flap) 
 5 healthy 
Kirzilikilic et al., 
2003(27) 




EV  aborted none no no  5 aborted 
2 2 MRA MRI 
DSA 
ICA EV  after tr. v no no  5 healthy 
3 3 MRI  DSA ACom
A 
EV  after tr. v no no  5 healthy 
Hussain et al., 2001 
(18) 






 no tr. cs yes no  5 NA 
Piotin et al., 
2001(42) 
1 3 MRA, 
DSA 
postpartum 
ICA EV  before tr. cs yes no  5 healthy 
 2 2 DSA ICA EV  at term v no no  4 healthy 
Shahabi et al.,  
2001 (48) 
1 3 DSA BA EV  after tr. cs yes no  5 good 
Jaeger et al., 2000 
(20) 
1 3 DSA ICA CLP yes contemp to 
tr. 
cs yes no  4 fair 
Meyers et al., 2000 
(34) 
1 1 DSA PCA CLP 
followed 
by EV  
 after tr. v no no  5 healthy 
2 3 DSA BA EV  after tr. v no no  5 healthy 
3 3 DSA PCom
A 
EV  before tr. cs yes no  5 healthy 
(twins) 
Barker et al., 1998 
(2) 
1 3 MRA MRI  PCom
A 
CLP  contemp to 
tr. 
cs yes no  5 healthy 
D'Haese et al., 
1997 (7) 
1 3 MRI MRA ICA CLP  contemp to 
tr. 
cs yes no yes 5 healthy 
Kriplani et al., 
1995(29) 
1 3 DSA ACom
A 
CLP  contemp to 
tr. 
cs yes no  5 fair 
2 3 DSA ICA CLP  before tr. v no no yes 5 healthy 
3 3 DSA PICA CLP  contemp to 
tr 
cs no rebleeding and 
hydrocephalus 
 5 healthy 
Aneurysm; ACA, Anterior Cerebral Artery; AComA, Anterior Communicating Artery; A, BA, Basilar Artery; cs, C-section; CSF, cerebrospinal fluid; CLP, Surgical Clipping; 
CTA, contemp., contemporary; CTangiography; DSA, Digital Subtraction Angiography; EV, endovascular treatment; GOS, Gloasgow Outcome Score; ICA, Internal Carotid 
Artery; MR, Magnetic Resonance; MRA, Magnetic Resonance Angiography; NA, not available; PCA, posterior cerebral artery; PComA, Posterior Communicating Artery; PICA, 
PosterioInferior Cerebellar Artery; SIADH, Syndrome of Inappropriate Antiduretic Hormone Secretion; tr., treatment;v, vaginal delivery; VA Vertebral Artery 
 
Parameter GOS 1-3 (n=8) n GOS 4-5 (n=44) n Statistical significancea  
Age (mean±SD; 
range; median) 
35.88±5.38 (28-42; 36) 
 






33.43±3.36 (28-38; 33) 
 
7 28.23±8.46 (9-39; median 31) 
 
39 p-value=0.119 
Trimester (n) First (0); second (0); third 
(8) 
 
8 First (4); second (10); third (30) 44 p-value=0.084 
Aneurysmal site (n) Anterior (6); posterior (2) 
 
8 Anterior (34); posterior (10) 
 
44 p-value=1.000 
PMH (n) Yes (1); no (not available) 
 
1 Yes (6); no (12) 
 
18 Not applicable 
Risk factors (n) Yes (3); no (not available) 
 
3 Yes (10); no (8)  
 
18 Not applicable 
Treatment modality 
(n) 
CLP (2); EV (3); none (3) 
 





Vaginal (1); caesarean (4); 
none (2) 
 




Timing of delivery 
(n) 
After treatment (0); at 
term (0); before treatment 
(5); contemporary to 
treatment (0) no treatment 




7 After treatment (15); at term (7); 
before treatment (7); 
contemporary to treatment (11) 
no treatment (1); aborted or 
death in utero (1) 
 
42 p-value=0.001 
Vasospasm (n) Not available  Yes (8); no (0) 
 
9 Not applicable 
General 
complications (n) 
Yes (6); no (1) 
 
7 Yes (10); no (33) 
 
43 p-value=0.003 
Emergency CS (n) Yes (4); no (4) 
 
8 Yes (19); no (22) 
 
41 p-value=1.000 
CSF shunt (n) Not available  Yes (5); no (not available) 
 
5 Not applicable 
Hunt-Hess grade at 
arrival (mean±SD; 
range; median) 
3.86±1.21 (2-5; 4) 
 
7 2.49±0.69 (2-5; median 2) 
 
37 p-value=0.004 
Fisher score at Equal to 4 (5); less than 4 7 Equal to 4 (18); less than 4 (10) 28 p-value=1.000 
arrival (n) (2) 
 
 
GCS at arrival 
(mean±SD; range; 
median) 
6.88±5.38 (3-14; 3) 
 
8 13.95±2.32 (3-15; median 15) 
 
43 p-value <0.001 
Parameter Apgar score 0-3 (n=7) n Apgar score 4-10 (n=37) n Statistical significancea  
Age (mean±SD; 
range; median) 
32.86±6.18 (25-42; 30) 
 







26.57±11.10 (10-38;  31) 
 
7 28.76±7.80 (9-39; median 30.5) 
 
36 p-value=0.533 
Trimester (n) First (2); second (0); third 
(5) 
 
7 First (2); second (9); third (25) 
 
36 p-value=0.435 
Aneurysmal site (n) Anterior (6); posterior (1) 
 
7 Anterior (29); posterior (8) 
 
37 p-value=1.000 
PMH (n) Yes (1); no (not available) 
 
1 Yes (3); no (9) 
 
12 Not applicable 
Risk factors (n) Yes (1); no (not available) 
 
1 Yes (7); no (8)  
 
15 Not applicable 
Treatment modality 
(n) 
CLP (1); EV (3); none (3) 
 
7 CLP (22); EV (15); none (0) 
 
37 p-value <0.001 
Modality of 
delivery (n) 
Vaginal (1); caesarean (3); 
none (3) 
 
7 Vaginal (9); caesarean (28); 
none (0) 
 
37 p-value <0.001 
Timing of delivery 
(n) 
After treatment (1); at 
term (0); before treatment 
(3); contemporary to 
treatment (0) no treatment 




7 After treatment (14); at term (7); 
before treatment (4); 
contemporary to treatment (12) 
no treatment (0); aborted or 
death in utero (0) 
 
37 p-value <0.001 
Vasospasm (n) Yes (1); no (not available) 
 
1 Yes (4); no (not available) 
 
4 Not applicable 
General 
complications (n) 
Yes (3); no (4) 
 
7 Yes (13); no (33) 
 
36 p-value=0.419 
Emergency CS (n) Yes (3); no (4) 
 
7 Yes (18); no (18) 
 
36 p-value=1.000 
Table 3:  statistical findings from pooled data analysis with respect to maternal and baby 
outcome. a Chi-squared test, exact Fisher’s test, chi-squared test for trend for categorical data, t-test, U 
. 	
CSF shunt (n) Not available  Yes (4); no (not available) 
 
4 Not applicable 
Hunt-Hess grade at 
arrival (mean±SD; 
range; median) 
3.50±1.22 (2-5; 3) 
 
6 2.52±0.77 (2-5; median 2) 
 
31 p-value=0.014  
Fisher score at 
arrival (n) 
Equal to 4 (4); less than 4 
(not available) 
4 Equal to 4 (17); less than 4 (9) 
 
26 Not applicable 
GCS at arrival 
(mean±SD; range; 
median) 
9.57±6.16 (3-15; 14) 
 
7 13.47±9.57 (3-15; median 15) 
 
36 p-value=0.047 
Parameter F Statistical 
significancea 
Partial η2 Observed 
power 
Maternal outcome R2=0.701 (adjusted R2=0.552) 
Treatment modality 1.728 0.197 0.117 0.329 
Timing of delivery 2.601 0.073 0.231 0.570 
Modality of delivery 1.893 0.181 0.068 0.263 
Hunt-Hess Grade 0.022 0.882 0.001 0.052 
GCS at arrival 3.945 0.058 0.132 0.481 
General complications 11.534 0.002 0.307 0.905 
Trimester 0.044 0.957 0.003 0.056 
Age 0.035 0.853 0.001 0.054 
Baby outcome R2=0.432 (adjusted R2=0.268) 
Treatment modality 0.444 0.645 0.028 0.116 
Timing of delivery 0.706 0.556 0.064 0.182 
Modality of delivery 0.671 0.419 0.021 0.125 
Hunt-Hess Grade 0.082 0.776 0.003 0.059 
GCS at arrival 1.701 0.202 0.052 0.244 
Table 4:  statistical findings from the multivariate pooled data analysis with respect to maternal and baby 
outcome. aGeneralized Linear Model. Also overall fitting raw and adjusted R2, F-statistics, partial η2 and observed 
power are reported. 
Abbreviations: GCS (Glasgow Coma Scale).	
	
 
	
